Kamari Pharma
Israel - Ness ZionaPharmaceutical
Focus: Kamari Pharma is an early-stage Israeli biotech founded in 2024 focused on TRPV3 inhibitors for rare dermatological and genetic skin disorders. The company is pre-revenue with a portfolio of four Phase 1 programs targeting niche indications.
Profile data last refreshed 2h ago · AI intelligence enriched 2mo ago
Open Jobs
2+2 this month
Stable — net +2 jobs in 30d
3 added, 1 removed. Backfill posture.
Should You Work at Kamari Pharma?
AI assessmentKamari Pharma represents a high-risk, high-reward early-stage bet suitable only for risk-tolerant scientists or entrepreneurs seeking ground-floor equity upside in a novel mechanism.
Why Work Here
- Ground-floor opportunity at a newly founded company with exclusive TRPV3 inhibitor platform in an underexplored therapeutic area.
- Focus on rare genetic skin disorders (Punctate Palmoplantar Keratoderma, Olmsted Syndrome, Lichen Simplex Chronicus) with limited treatment options and potential for accelerated pathways.
Data completeness
2/9 — Limited
Company HealthSolid
Pipeline
Early-stage
4 total
LOE Risk
Protected
No near-term cliffs
Hiring
Slowing
Jobs decreasing
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
KM-001 cream 1% 12 weeks treatment.
Punctate Palmoplantar Keratoderma Type 1Clinical Trials (1)
NCT05956314Assessment of KM-001 - Safety, Tolerability, and Efficacy in Patients With PPPK1 or PC
Phase 1Help build intelligence for Kamari Pharma
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.